Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 61 briefings

Reset all filters

Oncology

Oncology Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

ONCOLOGY · CLINICAL PRACTICE

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial

In this interim analysis, short-course radiotherapy followed by camrelizumab and CAPOX significantly improved 3-year event-free survival in patients with locally advanced rectal cancer, with a safety profile similar to long-course chemoradiotherapy followed by CAPOX. Comparison of this promising new treatment strategy with contemporary total neoadjuvant therapy strategies is warranted.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet OncologyNov 15, 2026

ONCOLOGY · REAL-WORLD COHORT

Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations

This guideline provides a practical framework for standardisation of clinical management of de novo metastatic nasopharyngeal carcinoma and identification of key evidence gaps for future research. We recommend that curative-intent treatment should be offered to medically fit patients with no more than three metastatic lesions in two or fewer organs at baseline or following response to systemic therapy; multimodality treatment (comprising immunochemotherapy, locoregional radiotherapy, metastasis-directed therapy, and maintenance therapy) is recommended.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet OncologyNov 15, 2026

ONCOLOGY · REAL-WORLD COHORT

Development of the Children's Oncology Group long-term follow-up guideline for cancer genetics evaluation in childhood cancer survivors

Raising awareness of this guideline is crucial to enhancing the integration of genetics into survivorship care and improving health outcomes for childhood cancer survivors with CPS. This Policy Review details the importance, development, and anticipated impact of this new guideline.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet OncologyNov 15, 2026

ONCOLOGY · PHASE I/II

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study

The risk-benefit ratio observed in the DALY 2-EU study supports consideration of zamto-cel as a second-line standard treatment option for patients with relapsed or refractory large B-cell lymphoma who are ineligible for transplantation. However, there is no evidence from randomised controlled trials in patients ineligible for transplantation.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet OncologyNov 15, 2026

ONCOLOGY · REAL-WORLD COHORT

Assessment of comprehensiveness of national cancer control plans using a multiagent artificial intelligence model: a global analysis

Our analysis suggests that NCCP comprehensiveness varies substantially between countries with consistent weaknesses in financing, outcome measurement, and contextual analysis. A shared health systems framework and scalable AI appraisal tools, such as PRISM, could support more complete, comparable, and actionable plans to strengthen cancer control globally by providing the possibility for rapid analysis of comprehensiveness of NCCPs and generation of timely, achievable, and evidence-informed, context-specific plans that use the latest data.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet OncologyNov 15, 2026

ONCOLOGY · CLINICAL PRACTICE

Alarming Resurgence of Colorectal Cancer Incidence Across Age Groups

Colorectal cancer incidence is unexpectedly rising across most age groups under 70 in the US after a 20-year decline, demanding urgent re-evaluation of screening and risk factors. The observed reversal in colorectal cancer incidence presents a significant challenge to current public health strategies and established clinical guidelines.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 13, 2026

ONCOLOGY · CLINICAL PRACTICE

Forever Chemicals Linked to Nearly Doubled Aggressive Breast Cancer Risk

High levels of specific 'forever chemicals' (PFAS) are strongly associated with a nearly doubled risk of aggressive breast cancer, highlighting a critical, potentially preventable environmental health concern. Current breast cancer prevention strategies primarily focus on modifiable lifestyle factors, genetic screening, and early detection through mammography.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

ONCOLOGY · PRECLINICAL

Fructose Uncovered as a Driver of Ovarian Cancer Metastasis Post-Chemotherapy

Fructose metabolism, particularly post-chemotherapy, may represent a novel and actionable therapeutic target to impede ovarian cancer metastasis. Ovarian cancer often presents at an advanced stage, and despite initial responses to chemotherapy, recurrence and metastasis remain the primary causes of morbidity and risk of death.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readScienceDailyNov 12, 2026

ONCOLOGY · CLINICAL PRACTICE

Decades-Old Mystery Solved: New Anti-Inflammatory Defense Found

A newly identified immune defense mechanism protects healthy cells from inflammation, opening new avenues for treating inflammatory diseases and cancer. This breakthrough offers a novel target for therapeutic interventions in a range of inflammatory conditions.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

ONCOLOGY · CLINICAL PRACTICE

Novel Therapy Tricks Cancer Cells into Self-Destruction

By harnessing cancer cells' own metabolic products, this innovative strategy offers a highly selective way to deliver destructive drugs directly to tumors. This targeted method promises to selectively eliminate cancer cells while leaving healthy tissues unharmed, addressing a major limitation of current chemotherapies.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

ONCOLOGY · PRECLINICAL

Surprising Diet-Gut Link Boosts Cancer Immunotherapy in Mice

Specific dietary interventions, unexpectedly including some 'unhealthy' diets, may enhance cancer immunotherapy efficacy (real-world effectiveness in the trial) through gut microbiome modulation. This challenges traditional assumptions about diet's role in cancer treatment, suggesting that certain dietary patterns could potentially be leveraged to optimize immunotherapy outcomes.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readScienceDailyNov 12, 2026

ONCOLOGY · REAL-WORLD COHORT

Focused Ultrasound & Gene Therapy Target Aggressive Brain Cancer

A new experimental approach uses focused ultrasound to precisely deliver gene-targeting nanoparticles, offering a multi-pronged attack on glioblastoma. Glioblastoma is notoriously challenging to treat, with current therapies offering limited survival benefits.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

Showing 12 of 61 medical briefings

Interactive Fact Check